The UK biotech investment landscape: challenges, opportunities and emerging trends

Yesterday, partner Ross Cummings from GJE’s biotech and advanced therapeutics team took part in a panel discussion at the Bio Integrates conference at Victoria House, London, on the outlook biotech investment in the UK. The discussion touched on this sector’s ever-changing funding landscape, from the level of capital availability, evolving investor behaviours, and the growing importance of evidencing a clear and realistic commercial strategy to help secure investment.

The high-level take home is that securing investment remains challenging in the UK biotech space following a contraction in the available capital after the surge in investment seen in 2021 following the COVID-19 pandemic. While M&A activity has remained steady, there has been a slow-down in the number of UK biotech public listings. However, overall growth has been seen over the last quarter, with UK biotech financing in Q1 of 2026 increasing to £552 million from £466 million seen in Q4 of 2025.

While the headline figures show reasons for optimism in the sector, the conference also highlighted several success stories, illustrating that capital remains available for the right opportunities. The following trends were identified in how companies are securing investment in the current climate.

Increasingly selective investments

The funding landscape has shifted towards what can be described as a “hyper-selectivity of capital.” Early-stage companies in their discovery phase that were once able to secure funding with promising preliminary testing and a compelling scientific hypothesis are now struggling to gain traction. Many investment sources appear to be increasingly risk-averse, preferring established, later-stage companies already positioned in the clinic. For companies yet to enter the clinic, investors have an increased appetite for comprehensive preclinical data packages, regulatory engagement, and a clear pathway to clinical trials. Additionally, a greater emphasis has been placed on commercial viability, from scalability, market alignment, and possessing the right team to drive commercialisation. This shift has manifested itself through an increase in the sourcing of US talent to provide strategic guidance for rising UK biotech entities, as well as access to deeper capital markets.

Data remains a cornerstone of value

Even in the light of an increased importance for commercial strategy, the fact remains that high-quality data is still the bedrock of securing investment in this space. As the field matures, both investors and patent offices are setting higher bars for data requirements. For investors, a strong set of preclinical data increases confidence and reduces the perceived level of risk. From a patent perspective, a coherent and compelling dataset demonstrating improvements over previous technologies is key to broad patent applications that have a strong chance of progressing to grant. There was agreement that this is key to securing investment.

There was also discussion of the importance of involving patient groups in the process and the advantages this can have in securing regulatory approval, which is of course essential to enable patients to benefit from these advanced therapies.

Strategic focus of assets

As a result of investment selectivity, we have seen companies move away from broader portfolios of less substantiated pipelines and instead are prioritising fewer, more developed assets. By concentrating resources on a single lead asset, platform or modality, investors are more likely to consider a sole well-considered and commercially viable opportunity over a host of more speculative projects.

This focussing also has direct implications for patent strategy. In view of the rising expectation for patent applications to demonstrate a clear and specific technical contribution, it is increasingly important to use targeted data to deliver a focussed and persuasive narrative for patentability. Strategic and timely use of data in patent applications can also help build a layered patent portfolio which captures specific innovations, rather than rely on a single “catch-all” filing. This approach can not only extend overall patent terms for individual assets, but creates discrete, well-defined assets that can be more readily licensed or sold.

In summary, while challenges remain in the funding environment for UK biotech, success continues to be seen in companies that align with the shifting requirements of today’s investors. Companies providing high-quality data coupled with a focussed commercial vision and purpose bolstered by a robust IP strategy are better positioned to stand out in this increasingly competitive environment.

GJE’s advanced therapeutics team regularly assists early-stage biotech and pharmaceutical companies seeking to protect their innovation. To discuss your IP strategy, please contact us: biotech@gje.com.